Ze Dong

1.7k total citations · 1 hit paper
25 papers, 642 citations indexed

About

Ze Dong is a scholar working on Molecular Biology, Organic Chemistry and Immunology. According to data from OpenAlex, Ze Dong has authored 25 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 9 papers in Organic Chemistry and 5 papers in Immunology. Recurrent topics in Ze Dong's work include RNA modifications and cancer (9 papers), Cancer-related gene regulation (6 papers) and Asymmetric Synthesis and Catalysis (4 papers). Ze Dong is often cited by papers focused on RNA modifications and cancer (9 papers), Cancer-related gene regulation (6 papers) and Asymmetric Synthesis and Catalysis (4 papers). Ze Dong collaborates with scholars based in China, United States and Germany. Ze Dong's co-authors include Cai‐Guang Yang, Yue Huang, Chune Dong, Hai‐Bing Zhou, Hongjiao Xu, Guofu Qiu, Zihao Zhang, Jianzhong Xi, Yilin Li and Dali Han and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Accounts of Chemical Research and Cell Metabolism.

In The Last Decade

Ze Dong

25 papers receiving 634 citations

Hit Papers

Tumors exploit FTO-mediated regulation of glycolytic meta... 2021 2026 2022 2024 2021 50 100 150 200 250

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ze Dong China 13 455 181 161 62 50 25 642
Hariharan Venkatesan United States 12 310 0.7× 122 0.7× 281 1.7× 40 0.6× 11 0.2× 21 617
Prakash B. Palde United States 12 454 1.0× 23 0.1× 299 1.9× 65 1.0× 31 0.6× 16 724
Kristin K. Brown United States 9 461 1.0× 62 0.3× 72 0.4× 33 0.5× 107 2.1× 11 545
Séverine Ravez France 13 355 0.8× 93 0.5× 375 2.3× 96 1.5× 15 0.3× 25 643
Qinsheng Sun China 18 576 1.3× 81 0.4× 293 1.8× 176 2.8× 31 0.6× 35 807
Mickaël Jean France 12 179 0.4× 32 0.2× 231 1.4× 48 0.8× 56 1.1× 27 426
Davide Esposito Italy 13 394 0.9× 37 0.2× 129 0.8× 91 1.5× 18 0.4× 18 473
Yong‐Cheng Ma China 13 275 0.6× 32 0.2× 344 2.1× 53 0.9× 13 0.3× 19 630
Kiranmayi Vemuri United States 8 103 0.2× 75 0.4× 148 0.9× 77 1.2× 28 0.6× 10 337
Matthew G. LaPorte United States 17 237 0.5× 27 0.1× 429 2.7× 57 0.9× 19 0.4× 37 711

Countries citing papers authored by Ze Dong

Since Specialization
Citations

This map shows the geographic impact of Ze Dong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ze Dong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ze Dong more than expected).

Fields of papers citing papers by Ze Dong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ze Dong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ze Dong. The network helps show where Ze Dong may publish in the future.

Co-authorship network of co-authors of Ze Dong

This figure shows the co-authorship network connecting the top 25 collaborators of Ze Dong. A scholar is included among the top collaborators of Ze Dong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ze Dong. Ze Dong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yang, Teng, Ze Dong, Yiqing Wang, et al.. (2025). Development of Orally Bioavailable FTO Inhibitors with Potent Antileukemia Efficacy. Journal of Medicinal Chemistry. 68(13). 13714–13727. 1 indexed citations
2.
Dong, Ze, et al.. (2025). A patenting perspective of fat mass and obesity associated protein (FTO) inhibitors: 2017–present. Expert Opinion on Therapeutic Patents. 35(6). 533–542. 3 indexed citations
3.
Liu, Lu, Ming Li, Xi Zhang, et al.. (2025). Development of 3-arylaminothiophenic-2-carboxylic acid derivatives as new FTO inhibitors showing potent antileukemia activities. European Journal of Medicinal Chemistry. 289. 117444–117444. 3 indexed citations
4.
Yan, Chao Guo, Qian Zhang, Pan Xiao, et al.. (2024). Structure‐Activity Relationships of 2‐(Arylthio)benzoic Acid FTO Inhibitors. Israel Journal of Chemistry. 64(3-4). 4 indexed citations
5.
Yang, Yinghong, et al.. (2024). Stearoylation cycle regulates the cell surface distribution of the PCP protein Vangl2. Proceedings of the National Academy of Sciences. 121(29). e2400569121–e2400569121. 5 indexed citations
6.
Liu, Lu, Yiqing Wang, Xi Zhang, et al.. (2024). Discovery of a potent PROTAC degrader for RNA demethylase FTO as antileukemic therapy. Acta Pharmaceutica Sinica B. 14(12). 5382–5392. 9 indexed citations
7.
Zhu, Heping, Xiaomin Song, Ming Li, et al.. (2023). Design, synthesis, and biological evaluation of novel spirocyclic compounds as potential anti-glioblastoma agents. European Journal of Medicinal Chemistry. 258. 115595–115595. 4 indexed citations
8.
Huang, Yue, et al.. (2023). Chemical Inhibitors Targeting the Oncogenic m6A Modifying Proteins. Accounts of Chemical Research. 56(21). 3010–3022. 46 indexed citations
9.
Xiao, Pan, Liang Chen, Lu Liu, et al.. (2023). Rational Design of RNA Demethylase FTO Inhibitors with Enhanced Antileukemia Drug-Like Properties. Journal of Medicinal Chemistry. 66(14). 9731–9752. 33 indexed citations
10.
He, Hailong, et al.. (2023). Excitation of maximal degeneracy and higher-order topology in phononic crystals. Physical Review Applied. 20(6). 3 indexed citations
11.
Xiao, Pan, Tao Zhang, Hongjiao Xu, et al.. (2022). Structure–Activity Relationships and Antileukemia Effects of the Tricyclic Benzoic Acid FTO Inhibitors. Journal of Medicinal Chemistry. 65(15). 10638–10654. 35 indexed citations
12.
Liu, Yi, Guanghao Liang, Hongjiao Xu, et al.. (2021). Tumors exploit FTO-mediated regulation of glycolytic metabolism to evade immune surveillance. Cell Metabolism. 33(6). 1221–1233.e11. 252 indexed citations breakdown →
13.
Yang, Teng, Ze Dong, Song Yang, et al.. (2021). Covalent sortase A inhibitor ML346 prevents Staphylococcus aureus infection of Galleria mellonella. RSC Medicinal Chemistry. 13(2). 138–149. 14 indexed citations
14.
Dong, Ze, Zhen Wang, Zhongqiang Guo, et al.. (2020). Structure–Activity Relationship of SPOP Inhibitors against Kidney Cancer. Journal of Medicinal Chemistry. 63(9). 4849–4866. 23 indexed citations
15.
Wang, Zhen, Hao Zhang, Baoen Chen, et al.. (2020). A Peptide Binder of E3 Ligase Adaptor SPOP Disrupts Oncogenic SPOP‐Protein Interactions in Kidney Cancer Cells. Chinese Journal of Chemistry. 39(2). 274–280. 4 indexed citations
16.
18.
Dong, Ze, Guofu Qiu, Hai‐Bing Zhou, & Chune Dong. (2012). Chiral squaramide as multiple H-bond donor organocatalysts for the asymmetric Michael addition of 1,3-dicarbonyl compounds to nitroolefins. Tetrahedron Asymmetry. 23(22-23). 1550–1556. 35 indexed citations
19.
Dong, Ze, Xiaoqing Jin, Pengcheng Wang, et al.. (2011). Novel bifunctional chiral squaramide-amine catalysts for highly enantioselective addition of mono and diketones to nitroalkenes. ARKIVOC. 2011(9). 367–380. 21 indexed citations
20.
Wang, Fei, Yuan Gao, Ling Zhang, et al.. (2010). A Pair of Windmill-Shaped Enantiomers from Lindera aggregata with Activity toward Improvement of Insulin Sensitivity. Organic Letters. 12(14). 3196–3199. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026